Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes
Menée auprès de patients atteints de diabète de type 1 (durée de suivi : 28 ans), cette étude analyse l'association entre la dose quotidienne d'insuline et le risque de cancer
JAMA Oncology, sous presse, 2022, résumé
Résumé en anglais
Previous studies among persons with type 1 diabetes (T1D) found a higher incidence of certain cancers in this population compared with the general population. However, no studies have evaluated the risk factors of cancer incidence in T1D. In the present study, using data from the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) study, we explored the associations of risk factors with cancer incidence in patients with T1D over a 28-year follow-up period.
